EpilepsyGTx: Revolutionizing Epilepsy Treatment Through Gene Therapy
EpilepsyGTx, a biotechnology company based in London, UK, is dedicated to the research and development of gene therapies to effectively treat focal refractory epilepsy. Recently, the company announced that it had raised $10 million in Seed funding, with UCL Technology Fund leading the investment round and Health Technology Holding also participating. The funds raised will be utilized to complete preclinical studies for their lead gene therapy program, EPY201, and to initiate a Phase 1/2a clinical study in humans suffering from focal refractory epilepsy.
Under the leadership of CEO Nicolas Koebel, EpilepsyGTx has developed a unique approach to administering gene therapy directly to the seizure focus in patients.
The process involves a minimally invasive surgical procedure in a hospital setting, where a thin cannula is inserted into the seizure focus to deliver the gene therapy. Unlike traditional methods such as resective surgery or laser ablation, EpilepsyGTx's approach does not require the permanent destruction of cerebral tissue. Additionally, their method targets only the seizure focus, unlike antiseizure medications which disperse throughout the entire body of patients.
By focusing on delivering a single dose of gene therapy to the specific site of seizures, EpilepsyGTx aims to provide a more effective and targeted treatment for patients suffering from focal refractory epilepsy. This innovative approach not only shows promise in enhancing patient outcomes but also highlights the potential for gene therapy to revolutionize the field of epilepsy treatment. With the successful completion of preclinical studies and the forthcoming Phase 1/2a clinical study, EpilepsyGTx is poised to make significant strides in addressing the unmet medical needs of individuals living with epilepsy.
They've invested in EpilepsyGTx
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK